

Texas Vaccine Providers Webinar Highlights – February 15, 2022

Review the highlights of the topics covered in the Feb. 15th webinar below or view the [full recording](#) for detailed information.

Opening Remarks

- On Friday, February 11, 2022, the FDA postponed the advisory committee meeting scheduled for Feb. 15th to discuss the authorization of Pfizer COVID-19 vaccine for children 6 months through 4 years of age. Based on the FDA’s preliminary assessment, and to allow more time to evaluate additional data, the FDA believes additional information regarding the ongoing evaluation of a third dose should be considered as part of their decision-making for potential authorization.
- Pfizer COVID-19 vaccine for children 6 months through 4 years is currently paused for ordering in VAOS. **Providers do not need to take any action if they have already placed an order for this vaccine.**

COVID-19 Vaccine Updates

- CDC clarified existing guidance for people who are **moderately or severely immunocompromised**, to confirm that those who previously received mRNA COVID-19 vaccines (Pfizer-BioNTech or Moderna) should receive a total of 4 doses – a primary series of 3 doses of an mRNA vaccine, plus 1 booster dose of an mRNA vaccine (4th dose).
- CDC provided new guidance for people who are **moderately or severely immunocompromised**:
 - [People who initiated vaccination with Johnson & Johnson’s Janssen](#) COVID-19 vaccine should receive a total of 3 doses – 1 Johnson & Johnson’s Janssen dose, **followed by 1 additional mRNA dose at least 28 days later**, then 1 booster dose at least 2 months after the 2nd (additional) dose. (mRNA vaccines are preferred for the booster.)
 - People who received a 3-dose mRNA COVID-19 vaccination series should receive the booster dose **3 months after the primary series** (instead of 5 months after the primary series).
- CDC [simplified recommendations](#) for vaccination after receipt of passive COVID-19 antibody products, **eliminating all vaccination deferral periods after receipt of these antibody products.**

COVID-19 Vaccine Digital Data Logger Guidance

- As a requirement to participate in the COVID-19 Vaccine Program, providers must have proper storage unit temperature monitoring equipment to help protect the viability of the COVID-19 vaccine product(s) in their inventory. COVID-19 Vaccine Program providers must have a continuous temperature monitoring device with a valid certificate of calibration, also known as a **digital data logger**, in each storage unit containing the COVID-19 vaccine. **Failure to have a valid data logger will prevent vaccine orders from being processed.**

COVID-19 Vaccine ImmTrac2 Reporting

- Providers administering doses of [Spikevax](#) COVID-19 vaccine should use the trade name “Spikevax 100mcg/0.5mL” when entering administered doses in ImmTrac2. Providers administering doses of Moderna COVID-19 vaccine should use the trade name “Moderna COVID-19 Vaccine.” Providers will phase out the Moderna COVID-19 Vaccine reporting codes as they use up their inventory and switch over to the Spikevax reporting code.

Provider Resources:

- [COVID-19 Vaccine Management Resources \(training and support materials\)](#)
- [ImmTrac2 User Training Site](#)
- [ImmTrac2 Forms and Documents](#)
- [COVID-19 Vaccine Provider Enrollment Information](#)
- [CDC Clinical Considerations for or Use of mRNA COVID-19 Vaccines](#)
- DSHS Provider Help Desk: (833) 832-7068, 8 a.m. to 5 p.m., Monday through Friday; Email: COVID19VacEnroll@dshs.texas.gov

Live Q&A:

Below are some of the questions DSHS subject matter experts answered during the webinar’s live Q&A sessions.

- Is a client who is not immunocompromised and who received one dose of J&J COVID-19 vaccine and a booster shot of Moderna COVID-19 vaccine considered up to date?
- If an immunocompromised client requests a third dose of COVID-19 vaccine 6 months after receiving their second dose of COVID-19 vaccine, should we administer a third dose and have them come back for a booster in 3 months?
- Is an adult client who has received two doses of AstraZeneca COVID-19 vaccine outside the U.S. eligible to receive a booster in the US?